Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor primarily indicated for the treatment of tardive dyskinesia, a condition characterized by involuntary, repetitive body movements. As… Read more
![Chemical structure of (2R,3R,11bR)-2-((L-Valyl)oxy)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydropyrido[2,1-a]isoquinoline 5(2H)-oxide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2R3R11bR-2-L-Valyloxy-3-isobutyl-910-dimethoxy-1346711b-hexahydropyrido21-aisoquinoline-52H-oxide.png&w=3840&q=75)
![Chemical structure of (2R,3R,11bR)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl (tert-butoxycarbonyl)-L-valinate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2102090-16-2-2R3R11bR-3-Isobutyl-910-dimethoxy-1346711b-hexahydro-2H-pyrido21-aisoquinolin-2-yl-tert-butoxycarbonyl-L-valinate.png&w=3840&q=75)
![Chemical structure of (2R,3R,11bR)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl D-valinate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1025504-59-9-2R3R11bR-3-Isobutyl-910-dimethoxy-1346711b-hexahydro-2H-pyrido21-aisoquinolin-2-yl-D-valinate.png&w=3840&q=75)
![Chemical structure of (2R,3S,11bS)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2R3S11bS-3-Isobutyl-910-dimethoxy-1346711b-hexahydro-2H-pyrido21-aisoquinolin-2-yl-L-valinate.png&w=3840&q=75)
![Chemical structure of (2S,3R,11bR)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2S3R11bR-3-Isobutyl-910-dimethoxy-1346711b-hexahydro-2H-pyrido21-aisoquinolin-2-yl-L-valinate.png&w=3840&q=75)
![Chemical structure of (2S,3S,11bS)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl D-valinate bis(4-methylbenzenesulfonate)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2S3S11bS-3-Isobutyl-910-dimethoxy-1346711b-hexahydro-2H-pyrido21-aisoquinolin-2-yl-D-valinate-bis4-methylbenzenesulfonate.png&w=3840&q=75)
![Chemical structure of (2S,3S,11bS)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2S3S11bS-3-Isobutyl-910-dimethoxy-1346711b-hexahydro-2H-pyrido21-aisoquinolin-2-yl-L-valinate.png&w=3840&q=75)
![Chemical structure of Bis((2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl) 2,2'-(carbonylbis(azanediyl))(2S,2'S)-bis(3-methylbutanoate)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FBis2R3R11bR-3-isobutyl-910-dimethoxy-1346711b-hexahydro-2H-pyrido21-aisoquinolin-2-yl-22-carbonylbisazanediyl2S2S-bis3-methylbutanoate.png&w=3840&q=75)
![Chemical structure of L-Allothreonine, 3-methyl-, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2237934-70-0-L-Allothreonine-3-methyl-2R3R11bR-1346711b-hexahydro-910-dimethoxy-3-2-methylpropyl-2H-benzoaquinolizin-2-yl-ester.png&w=3840&q=75)






Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor primarily indicated for the treatment of tardive dyskinesia, a condition characterized by involuntary, repetitive body movements. As a pharmaceutical agent, it functions by modulating dopamine release in the central nervous system to reduce these symptoms. This category contains a range of high-quality materials designed to support robust pharmaceutical analysis, including Valbenazine reference standards, process-related impurities, potential degradants, and relevant metabolites. Laboratories utilize these compounds for precise impurity profiling, method validation, and routine quality control testing. Furthermore, stable isotope-labelled Valbenazine is available to serve as an internal standard in mass spectrometry-based assays, ensuring accuracy and reliability when quantifying drug concentrations in complex matrices. These tools provide the necessary resources for maintaining compliance and consistency throughout the drug development and manufacturing lifecycle.